The value of specialty oncology drugs

Health Services Research

Volumn 45, Issue 1, 2010, Pages 115-132

  Goldman, Dana P ^a   Jena, Anupam B ^b   Lakdawalla, Darius N ^a   Malin, Jennifer L ^c   Malkin, Jesse D ^d   Sun, Eric ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d R and D Corporation   (United States)

Author keywords

Cost benefit analysis; Economic analysis; Oncology; Willingness to pay

Indexed keywords

BEVACIZUMAB; ERLOTINIB; IMATINIB; RITUXIMAB; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONSUMER ATTITUDE; CONTROLLED STUDY; COST CONTROL; DECISION MAKING; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE PLANNING; HUMAN; INCOME; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PATIENT COMPLIANCE; PRIVATE HEALTH INSURANCE; UTILIZATION REVIEW;

AGED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; FINANCING, PERSONAL; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; UNITED STATES;

EID: 74549189331     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/j.1475-6773.2009.01059.x     Document Type: Article

References (27)

1. Becker, G. S., K. M. Murphy T. J. Philipson. 2007. The Value of Life Near Its End and Terminal Care. Cambridge, MA : National Bureau of Economic Research.
2. Chernew, M. E., A. B. Rosen A. M. Fendrick. 2007 Value-Based Insurance Design Health Affairs 26 (2) : w195 203.
3. Contoyannis, P., J. Hurley, P. Grootendorst, S.-H. Jeon R. Tamblyn. 2005 Estimating the Price Elasticity of Expenditure for Prescription Drugs in the Presence of Non-linear Price Schedules: An Illustration from Quebec, Canada Health Economics 14 (9) : 909 923.
4. Dolan, P., J. A. Olsen, P. Menzel J. Richardson. 2003 An Inquiry into the Different Perspectives That Can Be Used When Eliciting Preferences in Health Health Economics 12 (7) : 545 551.
5. Gaynor, M., J. Li W. B. Vogt. 2006. Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits. National Bureau of Economic Research Inc., NBER Working Paper No. 12758. Cambridge, MA: National Bureau of Economic Research.
6. Goldman, D. P., G. F. Joyce, G. Lawless, W. H. Crown V. Willey. 2006 Benefit Design and Specialty Drug Use Health Affairs 25 (5) : 1319 1331.
7. Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross F. Kabbinavar. 2004 Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer New England Journal of Medicine 350 (23) : 2335 2342.
8. Jacobson, M., A. J. O'Malley, C. C. Earle, J. Pakes, P. Gaccione J. P. Newhouse. 2006 Does Reimbursement Influence Chemotherapy Treatment for Cancer Patients? Health Affairs 25 (2) : 437 443.
9. Jena, A. B. T. Philipson. 2007 Cost-Effectiveness as a Price Control Health Affairs 26 (3) : 696 703.
10. Kolata, G. A. Pollack. 2008. Cost Cancer Drug Offers Hope, but Also a Dilemma. New York Times.
11. Krupski, T. L., C. S. Saigal, J. Hanley, M. Schonlau M. S. Litwin. 2006 Patterns of Care for Men with Prostate Cancer after Failure of Primary Treatment Cancer 107 (2) : 258 265.
12. Lamont, E. B., J. E. II. Herndon, J. C. Weeks, I. C. Henderson, C. C. Earle, R. L. Schilsky N. A. Christakis. 2006 Measuring Disease-Free Survival and Cancer Relapse Using Medicare Claims from CALGB Breast Cancer Trial Participants (Companion to 9344) Journal of the National Cancer Institute 98 (18) : 1335 1338.
13. Lee, C. P., G. M. Chertow S. Zenios. 2009 An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard Value in Health 12 (1) : 80 7.
14. Lee, T. H. E. J. Emanuel. 2008 Tier 4 Drugs and the Fraying of the Social Compact New England Journal of Medicine 359 (4) : 333 335.
15. Liu, S. D. Chollet. 2006. Price and Income Elasticity of the Demand for Health Insurance and Health Care Services: A Critical Review of the Literature. Washington, DC: Mathematica Policy Research Inc.
16. Lubitz, J. D. G. F. Riley. 1993 Trends in Medicare Payments in the Last Year of Life New England Journal of Medicine 328 (15) : 1092 1096.
17. Nadler, E., B. Eckert P. J. Neumann. 2006 Do Oncologists Believe New Cancer Drugs Offer Good Value? The Oncologist 11 (2) : 90 5.
18. Neumann, P. J. M. Johannesson. 1994 The Willingness to Pay for In Vitro Fertilization: A Pilot Study Using Contingent Valuation Medical Care 32 (7) : 686 699.
19. Neumann, P. J., E. A. Sandberg, C. M. Bell, P. W. Stone R. H. Chapman. 2000 Are Pharmaceuticals Cost-Effective? A Review of the Evidence Health Affairs 19 (2) : 92 109.
20. Nord, E. 1999. Cost-Value Analysis in Health Care. Cambridge, UK : Cambridge University Press.
21. Pelletier, E. M., B. Shim, S. Goodman M. M. Amonkar. 2008 Epidemiology and Economic Burden of Brain Metastases among Patients with Primary Breast Cancer: Results from a US Claims Data Analysis Breast Cancer Research and Treatment 108 (2) : 297 305.
22. Philipson, T. J. A. B. Jena. 2006 Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs Forum for Health Economics and Policy 9 (2) : 1 31.
23. Rao, S., J. Kubisiak D. Gilden. 2004 Cost of Illness Associated with Metastatic Breast Cancer Breast Cancer Research and Treatment 83 (1) : 25 32.
24. Russell, L. B., M. R. Gold, J. E. Siegel, N. Daniels M. C. Weinstein. 1996 The Role of Cost-Effectiveness Analysis in Health and Medicine. Panel on Cost-Effectiveness in Health and Medicine Journal of American Medical Association 276 (14) : 1172 1177.
25. Tappenden, P., R. Jones, S. Paisley C. Carroll. 2007 The Cost-Effectiveness of Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer in England and Wales European Journal of Cancer 43 (17) : 2487 2494. (Pubitemid 350086932)
26. Ubel, P. A., R. A. Hirth, M. E. Chernew A. M. Fendrick. 2003 What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? Archives of Internal Medicine 163 (14) : 1637 1641.
27. Willey, V. J., M. F. Pollack, W. M. Lednar, W. N. Yang, C. Kennedy G. Lawless. 2008 Costs of Severely Ill Members and Specialty Medication Use in a Commercially Insured Population Health Affairs 27 (3) : 824 834.